Cresemba (isavuconazonium sulfate) - Astellas, Basilea
voriconazole - Generic mfg.
Noxafil (posaconazole) - Merck (MSD)
itraconazole - Generic mfg.
CYP51C Y319H and H349R substitutions cannot confer azole resistance in Aspergillus flavus NRRL 3357-5. (PubMed, Microbiol Spectr) - Jun 10, 2026 - "Both mutant strains exhibited the same susceptibility profiles to itraconazole, voriconazole, posaconazole, isavuconazole, echinocandins, and amphotericin B as the wild-type control. Our findings highlight that the presence of mutations in resistant isolates does not necessarily imply causality. By emphasizing the need for functional validation, this work helps prevent misinterpretation of neutral polymorphisms as resistance markers and improves the accuracy of molecular diagnostics and resistance surveillance in A. flavus." 
Journal
http://www.ncbi.nlm.nih.gov/pubmed/42262093
 
Alexey A Grum-Grzhimaylo; Bart Kraak; Jos Houbraken; Martin Meijer; Ya Bin Zhou
 
Jun 10, 2026
 
Prev Next